• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: SIEMENS HEALTHCARE DIAGNOSTICS INC. ATELLICA CH ENZYMATIC CREATININE_3 (ECRE3); ENZYMATIC METHOD, CREATININE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

SIEMENS HEALTHCARE DIAGNOSTICS INC. ATELLICA CH ENZYMATIC CREATININE_3 (ECRE3); ENZYMATIC METHOD, CREATININE Back to Search Results
Model Number N/A
Device Problem Low Test Results (2458)
Patient Problem No Clinical Signs, Symptoms or Conditions (4582)
Event Date 10/02/2023
Event Type  malfunction  
Event Description
The customer obtained discordant enzymatic creatinine_3 (ecre3) results for patient serum samples processed on the atellica ch 930 analyzer, serial number (s/n) (b)(6) reagent lot 123531.The discordant results were not reported to the physician(s).The discordant results were discovered when the customer performed post-analysis/review of results from patient samples with initial low ecre3 results.The customer retested the samples on a different analyzer and initial results for sample id (b)(4) and sample id (b)(4) were found to be discordant.There are no allegations of patient or user intervention or adverse health consequences due to the discordant ecre3 results.
 
Manufacturer Narrative
An outside of the united states (ous) customer contacted the siemens customer care center to report an observation of falsely depressed atellica ch enzymatic creatinine_3 (ecre3) patient results.Quality control (qc) recovered within acceptable ranges for all control levels.The calibration used in sample processing was acceptable.The interpretation of results section of the instructions for use (ifu) states, "results of this assay should always be interpreted in conjunction with the patient¿s medical history, clinical presentation, and other findings." the limitations section of the ifu states, "as with any chemical reaction, you must be alert to the possible effect of unknown interferences from medications or endogenous substances.The laboratory and physician must evaluate all patient results in light of the total clinical status of the patient." siemens is investigating.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ATELLICA CH ENZYMATIC CREATININE_3 (ECRE3)
Type of Device
ENZYMATIC METHOD, CREATININE
Manufacturer (Section D)
SIEMENS HEALTHCARE DIAGNOSTICS INC.
511 benedict ave.
tarrytown NY 10591
Manufacturer (Section G)
SIEMENS HEALTHCARE DIAGNOSTICS INC.
500 gbc drive po box 6101
registration # 2517506
newark DE 19714 6101
Manufacturer Contact
stacy loukos
333 coney st
east walpole, MA 02032
3392064073
MDR Report Key18181156
MDR Text Key328626041
Report Number2517506-2023-00251
Device Sequence Number1
Product Code JFY
UDI-Device Identifier00630414610948
UDI-Public00630414610948
Combination Product (y/n)N
Reporter Country CodeBR
PMA/PMN Number
K212223
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Foreign,Health Professional,User Facility
Reporter Occupation Other Health Care Professional
Type of Report Initial
Report Date 11/21/2023
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received11/21/2023
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Device Operator Health Professional
Device Expiration Date03/18/2024
Device Model NumberN/A
Device Catalogue Number11537216
Device Lot Number123531
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Date Manufacturer Received10/23/2023
Date Device Manufactured12/19/2022
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage A
Patient Sequence Number1
-
-